背景:特应性皮炎(AD)是最常见的皮肤病之一,但是围绕这种疾病对生活质量(QoL)的影响存在许多知识空白,心理健康,和管理AD所涉及的自付费用。关于AD多维负担的现有科学证据通常基于患者自己报告的测量研究。
方法:在这种情况下,MEASURE-AD试验是作为一个横截面,多中心,多国试验使用患者和医生报告的措施来描述成人中重度AD患者AD的多维负担。
结果:本文介绍了西班牙队列的结果。我们发现,患有中度至重度AD和高EASI评分(21.1-72)的西班牙成年人的疾病负担显着增加,高度严重的症状,如瘙痒和睡眠障碍,心理健康和QoL受损,提高医疗资源的利用率,与EASI评分较低(0-7或7.1-21)的患者相比,自付费用更多。
结论:这项研究提供了更好地了解疾病负担的信息,并确定AD管理中需要改进的方面。
BACKGROUND: Atopic dermatitis (AD) is one of the most prevalent skin diseases, but there are numerous knowledge gaps surrounding the impact this disease has on quality of life (QoL), mental health, and out-of-pocket expenses involved in the management of AD. The available scientific evidence on the multidimensional burden of AD is usually based on studies with measures reported by patients themselves.
METHODS: In this context, the MEASURE-AD trial was developed as a cross-sectional, multicenter, multinational trial using patient- and physician-reported measures to characterize the multidimensional burden of AD in adults with moderate-to-severe AD.
RESULTS: This paper presents the results of the Spanish cohort. We found that Spanish adults with moderate-to-severe AD and high EASI score (21.1-72) had a significantly increased disease burden, high severity of symptoms such as itch and sleep disturbances, impaired mental health and QoL, higher use of health care resources, and more out-of-pocket expenses than patients with low EASI scores (0-7 or 7.1-21).
CONCLUSIONS: This study provides information to better understand disease burden, and identify aspects to be improved in the management of AD.